Bank of New York Mellon Corp Decreases Holdings in Twist Bioscience Co. (NASDAQ:TWST)

Bank of New York Mellon Corp decreased its stake in shares of Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 40.4% during the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 689,031 shares of the company's stock after selling 466,419 shares during the quarter. Bank of New York Mellon Corp owned 1.18% of Twist Bioscience worth $33,955,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Artisan Partners Limited Partnership boosted its position in shares of Twist Bioscience by 111.3% during the 4th quarter. Artisan Partners Limited Partnership now owns 3,723,305 shares of the company's stock valued at $137,241,000 after acquiring an additional 1,961,621 shares in the last quarter. Nikko Asset Management Americas Inc. boosted its position in shares of Twist Bioscience by 2.9% during the 4th quarter. Nikko Asset Management Americas Inc. now owns 3,583,443 shares of the company's stock valued at $131,835,000 after acquiring an additional 99,511 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Twist Bioscience by 29.0% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,267,708 shares of the company's stock valued at $46,732,000 after acquiring an additional 284,884 shares in the last quarter. Baillie Gifford & Co. boosted its position in shares of Twist Bioscience by 12.1% during the 1st quarter. Baillie Gifford & Co. now owns 1,227,528 shares of the company's stock valued at $42,116,000 after acquiring an additional 132,770 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its position in shares of Twist Bioscience by 1.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 448,232 shares of the company's stock valued at $16,522,000 after acquiring an additional 5,728 shares in the last quarter.

Analysts Set New Price Targets

TWST has been the topic of several recent research reports. Robert W. Baird lifted their target price on shares of Twist Bioscience from $40.00 to $46.00 and gave the company an "outperform" rating in a research report on Monday, August 5th. Scotiabank raised their price target on shares of Twist Bioscience from $43.00 to $48.00 and gave the company a "sector outperform" rating in a report on Monday, May 6th. Guggenheim initiated coverage on shares of Twist Bioscience in a report on Tuesday, June 4th. They issued a "buy" rating and a $53.00 price target for the company. JPMorgan Chase & Co. raised their price target on shares of Twist Bioscience from $28.00 to $35.00 and gave the company an "underweight" rating in a report on Monday, August 5th. Finally, Barclays lowered their price target on shares of Twist Bioscience from $60.00 to $55.00 and set an "overweight" rating for the company in a report on Monday, August 5th. One research analyst has rated the stock with a sell rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $48.22.

Insider Transactions at Twist Bioscience

In other news, CEO Emily M. Leproust sold 2,408 shares of Twist Bioscience stock in a transaction on Thursday, June 6th. The shares were sold at an average price of $51.33, for a total transaction of $123,602.64. Following the transaction, the chief executive officer now directly owns 507,578 shares of the company's stock, valued at $26,053,978.74. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In related news, CEO Emily M. Leproust sold 2,408 shares of the business's stock in a transaction on Thursday, June 6th. The shares were sold at an average price of $51.33, for a total value of $123,602.64. Following the sale, the chief executive officer now directly owns 507,578 shares of the company's stock, valued at approximately $26,053,978.74. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Emily M. Leproust sold 5,139 shares of the business's stock in a transaction on Monday, August 5th. The shares were sold at an average price of $39.93, for a total transaction of $205,200.27. Following the completion of the sale, the chief executive officer now directly owns 499,593 shares in the company, valued at $19,948,748.49. The disclosure for this sale can be found here. Insiders have sold a total of 21,327 shares of company stock valued at $978,760 over the last three months. 3.92% of the stock is currently owned by corporate insiders.

Twist Bioscience Stock Down 5.3 %

TWST stock traded down $2.28 during midday trading on Tuesday, reaching $40.96. The company's stock had a trading volume of 964,461 shares, compared to its average volume of 1,016,564. Twist Bioscience Co. has a 52 week low of $14.42 and a 52 week high of $60.90. The stock has a market cap of $2.40 billion, a PE ratio of -12.19 and a beta of 1.76. The business's 50-day simple moving average is $48.76 and its 200-day simple moving average is $42.68.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last announced its quarterly earnings results on Friday, August 2nd. The company reported ($1.47) earnings per share for the quarter, missing analysts' consensus estimates of ($0.76) by ($0.71). The firm had revenue of $81.50 million for the quarter, compared to the consensus estimate of $77.40 million. Twist Bioscience had a negative return on equity of 32.17% and a negative net margin of 74.63%. The company's revenue for the quarter was up 27.7% compared to the same quarter last year. During the same period in the prior year, the business earned ($1.01) earnings per share. As a group, equities analysts forecast that Twist Bioscience Co. will post -3.13 earnings per share for the current fiscal year.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.